Answers are grounded in this paper and cite their sources.
Introduction: This study aims to analyze common adverse effects following immunization that are temporally associated after receiving the above 2 doses of ChAdOx1 nCoV-19 Vaccine (Covishield) COVID-19 vaccines among health-care worker from January 2021 to April 2021, in the central region of India in a tertiary care hospital. Materials and Methods: A surveillance-based study was conducted between January 2021 and April 2021 among the health-care worker of the tertiary care hospital in the central part of India. The study was designed to identify the adverse effects reported after receiving a ChAdOx1 nCoV-19 Vaccine (Covishield) COVID-19 vaccination and demographic details were collected. Results: Within 48 h of the initial immunization dose, 651 mild adverse effects in all participants were documented. Headache ( n = 168, 16%), fever ( n = 105, 10%), fatigue ( n = 115, 11%), and muscular discomfort ( n = 115, 10%) were among the frequent side effects. One hundred and five minor adverse effects were reported between 3 and 7 days. No major adverse effects were observed after the first and second doses of vaccine. Conclusion: The first 48 h were the most common observational period for the short-term adverse effects of both dosages. After 15 days of both doses, the incidence declined for consecutive weeks until it was completely absent. The symptoms were transient and of a minor in nature. There were no documented severe vaccine-related side effects. Our research demonstrated that the vaccination had a decreased adverse event profile, was safe, and was well-tolerated.
No takes yet. Share an insight, caveat, or question.
Goldar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: